{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:00:34Z","timestamp":1782939634980,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Accurate estimation of carrier probabilities of cancer susceptibility gene mutations is an important part of pre-test genetic counselling. Many predictive models are available but their applicability in the Asian population is uncertain. We evaluated the performance of five <jats:italic>BRCA<\/jats:italic> mutation risk predictive models in a Chinese cohort of 647 women, who underwent germline DNA sequencing of a cancer susceptibility gene panel. Using areas under the curve (AUCs) on receiver operating characteristics (ROC) curves as performance measures, the models did comparably well as in western cohorts (BOADICEA 0.75, BRCAPRO 0.73, Penn II 0.69, Myriad 0.68). For unaffected women with family history of breast or ovarian cancer (n\u2009=\u2009144), BOADICEA, BRCAPRO, and Tyrer-Cuzick models had excellent performance (AUC 0.93, 0.92, and 0.92, respectively). For women with both personal and family history of breast or ovarian cancer (n\u2009=\u2009241), all models performed fairly well (BOADICEA 0.79, BRCAPRO 0.79, Penn II 0.75, Myriad 0.70). For women with personal history of breast or ovarian cancer but no family history (n\u2009=\u2009262), most models did poorly. Between the two well-performed models, BOADICEA underestimated mutation risks while BRCAPRO overestimated mutation risks (expected\/observed ratio 0.67 and 2.34, respectively). Among 424 women with personal history of breast cancer and available tumor ER\/PR\/HER2 data, the predictive models performed better for women with triple negative breast cancer (AUC 0.74 to 0.80) than for women with luminal or HER2 overexpressed breast cancer (AUC 0.63 to 0.69). However, incorporating ER\/PR\/HER2 status into the BOADICEA model calculation did not improve its predictive accuracy.<\/jats:p>","DOI":"10.1038\/s41598-019-46707-6","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T10:50:58Z","timestamp":1563187858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan"],"prefix":"10.1038","volume":"9","author":[{"given":"Fei-Hung","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Alison","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhih-Wei","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Pin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Fang","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max M.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Suei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"46707_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford, D. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. American journal of human genetics 62, 676\u2013689 (1998).","journal-title":"American journal of human genetics"},{"key":"46707_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American journal of human genetics 72, 1117\u20131130, https:\/\/doi.org\/10.1086\/375033 (2003).","journal-title":"American journal of human genetics"},{"key":"46707_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/jco.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen, S. & Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25, 1329\u20131333, https:\/\/doi.org\/10.1200\/jco.2006.09.1066 (2007).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"46707_CR4","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1001\/jama.2018.5330","volume":"319","author":"J Gill","year":"2018","unstructured":"Gill, J., Obley, A. J. & Prasad, V. Direct-to-Consumer Genetic Testing: The Implications of the US FDA\u2019s First Marketing Authorization for BRCA Mutation Testing. JAMA: the journal of the American Medical Association 319, 2377\u20132378, https:\/\/doi.org\/10.1001\/jama.2018.5330 (2018).","journal-title":"JAMA: the journal of the American Medical Association"},{"key":"46707_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.7326\/m13-2747","volume":"160","author":"VA Moyer","year":"2014","unstructured":"Moyer, V. A. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160, 271\u2013281, https:\/\/doi.org\/10.7326\/m13-2747 (2014).","journal-title":"Ann Intern Med"},{"key":"46707_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jamaoncol.2015.3048","volume":"1","author":"J Armstrong","year":"2015","unstructured":"Armstrong, J. et al. Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study. JAMA oncology 1, 1251\u20131260, https:\/\/doi.org\/10.1001\/jamaoncol.2015.3048 (2015).","journal-title":"JAMA oncology"},{"key":"46707_CR7","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","volume":"33","author":"ME Robson","year":"2015","unstructured":"Robson, M. E. et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 33, 3660\u20133667, https:\/\/doi.org\/10.1200\/JCO.2015.63.0996 (2015).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"46707_CR8","unstructured":"ACOG bulletin 182 Hereditary Breast and Ovarian Cancer Syndrome 2017.pdf."},{"key":"46707_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10897-012-9547-1","volume":"22","author":"JL Berliner","year":"2013","unstructured":"Berliner, J. L., Fay, A. M., Cummings, S. A., Burnett, B. & Tillmanns, T. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. Journal of genetic counseling 22, 155\u2013163, https:\/\/doi.org\/10.1007\/s10897-012-9547-1 (2013).","journal-title":"Journal of genetic counseling"},{"key":"46707_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/bjc.2013.730","volume":"110","author":"AJ Lee","year":"2014","unstructured":"Lee, A. J. et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. British journal of cancer 110, 535\u2013545, https:\/\/doi.org\/10.1038\/bjc.2013.730 (2014).","journal-title":"British journal of cancer"},{"key":"46707_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1086\/301670","volume":"62","author":"G Parmigiani","year":"1998","unstructured":"Parmigiani, G., Berry, D. & Aguilar, O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. American journal of human genetics 62, 145\u2013158 (1998).","journal-title":"American journal of human genetics"},{"key":"46707_CR12","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank, T. S. et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20, 1480\u20131490 (2002).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"46707_CR13","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/nejm199705153362002","volume":"336","author":"FJ Couch","year":"1997","unstructured":"Couch, F. J. et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. The New England journal of medicine 336, 1409\u20131415, https:\/\/doi.org\/10.1056\/nejm199705153362002 (1997).","journal-title":"The New England journal of medicine"},{"key":"46707_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/jmg.2003.017996","volume":"41","author":"DG Evans","year":"2004","unstructured":"Evans, D. G. et al. A new scoring system for the chances of identifying a BRCA1\/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41, 474\u2013480 (2004).","journal-title":"J Med Genet"},{"key":"46707_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer, J., Duffy, S. W. & Cuzick, J. A breast cancer prediction model incorporating familial and personal risk factors. Statistics in medicine 23, 1111\u20131130, https:\/\/doi.org\/10.1002\/sim.1668 (2004).","journal-title":"Statistics in medicine"},{"key":"46707_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10689-010-9348-3","volume":"9","author":"NM Lindor","year":"2010","unstructured":"Lindor, N. M. et al. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Familial cancer 9, 495\u2013502, https:\/\/doi.org\/10.1007\/s10689-010-9348-3 (2010).","journal-title":"Familial cancer"},{"key":"46707_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-017-4247-z","volume":"164","author":"JA Cintolo-Gonzalez","year":"2017","unstructured":"Cintolo-Gonzalez, J. A. et al. Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast cancer research and treatment 164, 263\u2013284, https:\/\/doi.org\/10.1007\/s10549-017-4247-z (2017).","journal-title":"Breast cancer research and treatment"},{"key":"46707_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10549-014-2987-6","volume":"145","author":"AG Arnold","year":"2014","unstructured":"Arnold, A. G. et al. Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast cancer research and treatment 145, 625\u2013634, https:\/\/doi.org\/10.1007\/s10549-014-2987-6 (2014).","journal-title":"Breast cancer research and treatment"},{"key":"46707_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3233\/BD-2007-27102","volume":"27","author":"J Culver","year":"2006","unstructured":"Culver, J., Lowstuter, K. & Bowling, L. Assessing breast cancer risk and BRCA1\/2 carrier probability. Breast Dis 27, 5\u201320 (2006).","journal-title":"Breast Dis"},{"key":"46707_CR20","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/bcr1365","volume":"8","author":"AC Antoniou","year":"2006","unstructured":"Antoniou, A. C. et al. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast cancer research: BCR 8, R3, https:\/\/doi.org\/10.1186\/bcr1365 (2006).","journal-title":"Breast cancer research: BCR"},{"key":"46707_CR21","doi-asserted-by":"publisher","first-page":"R59","DOI":"10.1186\/bcr2118","volume":"10","author":"E Thirthagiri","year":"2008","unstructured":"Thirthagiri, E. et al. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast cancer research: BCR 10, R59, https:\/\/doi.org\/10.1186\/bcr2118 (2008).","journal-title":"Breast cancer research: BCR"},{"key":"46707_CR22","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10549-012-2022-8","volume":"134","author":"E Kang","year":"2012","unstructured":"Kang, E. et al. Accuracy of BRCA1\/2 mutation prediction models in Korean breast cancer patients. Breast cancer research and treatment 134, 1189\u20131197, https:\/\/doi.org\/10.1007\/s10549-012-2022-8 (2012).","journal-title":"Breast cancer research and treatment"},{"key":"46707_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/jmedgenet-2017-105073","volume":"55","author":"W Chew","year":"2018","unstructured":"Chew, W. et al. Evaluation of the relative effectiveness of the 2017 updated Manchester scoring system for predicting BRCA1\/2 mutations in a Southeast Asian country. J Med Genet 55, 344\u2013350, https:\/\/doi.org\/10.1136\/jmedgenet-2017-105073 (2018).","journal-title":"J Med Genet"},{"key":"46707_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10549-008-0181-4","volume":"116","author":"NY Rao","year":"2009","unstructured":"Rao, N. Y. et al. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients. Breast cancer research and treatment 116, 563\u2013570, https:\/\/doi.org\/10.1007\/s10549-008-0181-4 (2009).","journal-title":"Breast cancer research and treatment"},{"key":"46707_CR25","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s00268-011-1406-y","volume":"36","author":"A Kwong","year":"2012","unstructured":"Kwong, A. et al. Accuracy of BRCA1\/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. World journal of surgery 36, 702\u2013713, https:\/\/doi.org\/10.1007\/s00268-011-1406-y (2012).","journal-title":"World journal of surgery"},{"key":"46707_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ygyno.2017.01.026","volume":"145","author":"KJ Eoh","year":"2017","unstructured":"Eoh, K. J. et al. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients. Gynecol Oncol 145, 137\u2013141, https:\/\/doi.org\/10.1016\/j.ygyno.2017.01.026 (2017).","journal-title":"Gynecol Oncol"},{"key":"46707_CR27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/jmg.2007.056556","volume":"45","author":"AC Antoniou","year":"2008","unstructured":"Antoniou, A. C. et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45, 425\u2013431, https:\/\/doi.org\/10.1136\/jmg.2007.056556 (2008).","journal-title":"J Med Genet"},{"key":"46707_CR28","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/jnci\/94.11.844","volume":"94","author":"DM Euhus","year":"2002","unstructured":"Euhus, D. M. et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. Journal of the National Cancer Institute 94, 844\u2013851 (2002).","journal-title":"Journal of the National Cancer Institute"},{"key":"46707_CR29","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1200\/jco.2008.16.8310","volume":"26","author":"AW Kurian","year":"2008","unstructured":"Kurian, A. W. et al. Performance of BRCA1\/2 mutation prediction models in Asian Americans. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26, 4752\u20134758, https:\/\/doi.org\/10.1200\/jco.2008.16.8310 (2008).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"46707_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/jmg.2003.013623","volume":"41","author":"F Marroni","year":"2004","unstructured":"Marroni, F. et al. Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 41, 278\u2013285 (2004).","journal-title":"J Med Genet"},{"key":"46707_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-011-1596-x","volume":"132","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. Breast cancer research and treatment 132, 421\u2013428, https:\/\/doi.org\/10.1007\/s10549-011-1596-x (2012).","journal-title":"Breast cancer research and treatment"},{"key":"46707_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10689-012-9531-9","volume":"11","author":"MA de Bruin","year":"2012","unstructured":"de Bruin, M. A. et al. Breast cancer risk factors differ between Asian and white women with BRCA1\/2 mutations. Familial cancer 11, 429\u2013439, https:\/\/doi.org\/10.1007\/s10689-012-9531-9 (2012).","journal-title":"Familial cancer"},{"key":"46707_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4048\/jbc.2013.16.4.357","volume":"16","author":"H Kim","year":"2013","unstructured":"Kim, H. & Choi, D. H. Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer. Journal of breast cancer 16, 357\u2013365 (2013).","journal-title":"Journal of breast cancer"},{"key":"46707_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4229-5","volume":"18","author":"YA Wang","year":"2018","unstructured":"Wang, Y. A. et al. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC cancer 18, 315, https:\/\/doi.org\/10.1186\/s12885-018-4229-5 (2018).","journal-title":"BMC cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46707-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46707-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46707-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:37:10Z","timestamp":1671277030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46707-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46707"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46707-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]},"assertion":[{"value":"17 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10229"}}